New drug combo tested as second chance for tough liver cancers
NCT ID NCT05199285
Summary
This study tested whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, could help control advanced liver cancer in patients whose cancer had continued to grow despite receiving the standard first-line treatment. The trial involved a small group of 15 adults with advanced, inoperable liver cancer. The goal was to see if this new drug combination could shrink tumors and extend life for patients who had run out of standard options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Alabama- Birmingham
Birmingham, Alabama, 35233, United States
-
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.